Advancing Kratom Science and Regulation: A Comparative Framework With Cannabis.

Kratom, a psychoactive botanical used historically in Southeast Asia and increasingly in the United States, has limited evidence for its analgesic, stimulant, and mood-altering effects. This narrative review distinguishes between whole leaf products and those enriched with active constituents or semisynthetic derivatives, which differ in chemistry, pharmacology, and risk. Priorities include developing chemically defined botanical preparations, validated analytical methods, and human studies linking exposure to effect. The authors suggest a dual regulatory track: enhanced quality standards for botanical products and conventional drug development pathways for enriched or semisynthetic constituents. Coordinated federal support is needed to align product standardization, early phase trials, and comparative evaluations across product classes to examine therapeutic applications while safeguarding public health.

Study at a glance

Abstract

Kratom ( Mitragyna speciosa ) is a psychoactive botanical with a long history of use in Southeast Asia and growing uptake in the United States for its analgesic, stimulant, and mood-altering properties. The evidence base remains limited, and retail products vary widely in composition and potency. This narrative review highlights what is known about kratom's pharmacology and suggests a practical research and regulatory path toward evaluating its potential therapeutic applications within current regulatory frameworks, based on lessons from cannabis. A central distinction is between whole leaf products and those that are enriched in active constituents or that include semisynthetic derivatives. Because these categories differ in chemistry, pharmacology, and expected risk, they require different evidence standards. Priorities include development of chemically defined botanical preparations, validated analytical methods, and human studies that link exposure to effect through pharmacokinetic and pharmacodynamic modeling, abuse liability assessment, and cognitive and behavioral testing. The regulatory framework for kratom should consider a dual track. This includes enhanced standards for product quality, including composition, purity, labeling, and safety surveillance for botanical products, and conventional drug development pathways for enriched or semisynthetic constituents that include toxicology and human abuse potential studies. Coordinated federal support is urgently needed to align product standardization, early phase trials, and comparative evaluations across product classes. With this structure, kratom's possible therapeutic applications can be examined while safeguarding public health.